NO313193B1 - Nye forbindelser for anvendelse som neuro-protektive midler - Google Patents

Nye forbindelser for anvendelse som neuro-protektive midler Download PDF

Info

Publication number
NO313193B1
NO313193B1 NO19992226A NO992226A NO313193B1 NO 313193 B1 NO313193 B1 NO 313193B1 NO 19992226 A NO19992226 A NO 19992226A NO 992226 A NO992226 A NO 992226A NO 313193 B1 NO313193 B1 NO 313193B1
Authority
NO
Norway
Prior art keywords
mmol
alkyl
butyl
ethyl
hydroxyphenyl
Prior art date
Application number
NO19992226A
Other languages
English (en)
Norwegian (no)
Other versions
NO992226D0 (no
NO992226L (no
Inventor
Lawrence Joseph Heinz
Jill A Panetta
Michael Leroy Phillips
John K Shadle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO992226D0 publication Critical patent/NO992226D0/no
Publication of NO992226L publication Critical patent/NO992226L/no
Publication of NO313193B1 publication Critical patent/NO313193B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19992226A 1996-10-07 1999-05-07 Nye forbindelser for anvendelse som neuro-protektive midler NO313193B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2756096P 1996-10-07 1996-10-07
PCT/US1997/017963 WO1998015274A1 (en) 1996-10-07 1997-10-06 Novel compounds useful as neuro-protective agents

Publications (3)

Publication Number Publication Date
NO992226D0 NO992226D0 (no) 1999-05-07
NO992226L NO992226L (no) 1999-05-27
NO313193B1 true NO313193B1 (no) 2002-08-26

Family

ID=21838447

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992226A NO313193B1 (no) 1996-10-07 1999-05-07 Nye forbindelser for anvendelse som neuro-protektive midler

Country Status (19)

Country Link
US (4) US6156748A (pt)
EP (1) EP0971709B1 (pt)
CN (1) CN1239889A (pt)
AT (1) ATE240728T1 (pt)
AU (1) AU721355B2 (pt)
CA (1) CA2270661A1 (pt)
CZ (1) CZ166399A3 (pt)
DE (1) DE69722258T2 (pt)
DK (1) DK0971709T3 (pt)
EA (1) EA001713B1 (pt)
ES (1) ES2199353T3 (pt)
HU (1) HUP9904682A3 (pt)
ID (1) ID21472A (pt)
IL (1) IL129748A (pt)
NO (1) NO313193B1 (pt)
NZ (1) NZ335610A (pt)
PT (1) PT971709E (pt)
TR (1) TR199901559T2 (pt)
WO (1) WO1998015274A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952360A (en) * 1997-08-28 1999-09-14 Eli Lilly And Company Method for treating neuropathic pain
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
CA2302294A1 (en) * 1997-08-28 1999-03-04 Harlan Edgar Shannon Method for treating pain
JP2001519341A (ja) * 1997-10-06 2001-10-23 イーライ・リリー・アンド・カンパニー 神経保護剤として有用な新規化合物
IT1300055B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
FR2812546B1 (fr) * 2000-08-01 2008-11-21 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
DK1285651T3 (da) 2000-04-28 2010-12-13 Takeda Pharmaceutical Melanin-koncentrerende hormon-antagonister
CA2435820A1 (en) * 2001-02-08 2002-08-15 Karo Bio Ab Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
US7179808B2 (en) 2002-07-03 2007-02-20 Janssen Pharmaceutica N.V. Substituted heteroaryl and heterocyclic compounds useful in treating inflammatory disorders
EP3842055A1 (en) 2003-02-04 2021-06-30 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
TW200505913A (en) 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
US7353897B2 (en) * 2003-07-23 2008-04-08 Fernandez Dennis S Telematic method and apparatus with integrated power source
US7550439B2 (en) 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
JP5305914B2 (ja) 2005-11-15 2013-10-02 大塚製薬株式会社 オキサゾール化合物及び医薬組成物
EP2614549B1 (de) 2010-09-06 2016-04-27 Aigys AG Betankbarer akku
US10881162B2 (en) 2015-05-07 2021-01-05 Exero Labs LLC Device for minimizing impact of collisions for a helmet
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
DE3425118A1 (de) * 1984-07-07 1986-01-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue redox-indikatoren
GB8531608D0 (en) * 1985-12-23 1986-02-05 Beecham Group Plc Treatment
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2009470A1 (en) * 1989-02-08 1990-08-08 Yu Momose Oxazole compounds and their use
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
DK0513379T3 (da) * 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
US5633271A (en) * 1992-05-26 1997-05-27 E. I. Du Pont De Nemours And Company Arthropodicidal oxazolines and thiazolines
DE4304197A1 (de) * 1993-02-12 1994-08-18 Bayer Ag Substituierte Oxazole
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5952360A (en) * 1997-08-28 1999-09-14 Eli Lilly And Company Method for treating neuropathic pain
CA2302294A1 (en) * 1997-08-28 1999-03-04 Harlan Edgar Shannon Method for treating pain
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
JP2001519341A (ja) * 1997-10-06 2001-10-23 イーライ・リリー・アンド・カンパニー 神経保護剤として有用な新規化合物

Also Published As

Publication number Publication date
US6423709B1 (en) 2002-07-23
IL129748A (en) 2003-11-23
CA2270661A1 (en) 1998-04-16
ID21472A (id) 1999-06-17
WO1998015274A1 (en) 1998-04-16
ES2199353T3 (es) 2004-02-16
US6166216A (en) 2000-12-26
DK0971709T3 (da) 2003-09-22
EA001713B1 (ru) 2001-08-27
NO992226D0 (no) 1999-05-07
AU721355B2 (en) 2000-06-29
EP0971709A4 (en) 2001-04-11
HUP9904682A3 (en) 2001-09-28
US20020065274A1 (en) 2002-05-30
HUP9904682A2 (hu) 2000-05-28
DE69722258D1 (de) 2003-06-26
ATE240728T1 (de) 2003-06-15
EP0971709B1 (en) 2003-05-21
TR199901559T2 (xx) 1999-09-21
EP0971709A1 (en) 2000-01-19
DE69722258T2 (de) 2004-03-18
AU4745997A (en) 1998-05-05
CN1239889A (zh) 1999-12-29
IL129748A0 (en) 2000-02-29
PT971709E (pt) 2003-09-30
US6156748A (en) 2000-12-05
NO992226L (no) 1999-05-27
EA199900362A1 (ru) 2000-02-28
NZ335610A (en) 2000-10-27
US6380213B1 (en) 2002-04-30
CZ166399A3 (cs) 1999-11-17

Similar Documents

Publication Publication Date Title
NO313193B1 (no) Nye forbindelser for anvendelse som neuro-protektive midler
RU2514427C2 (ru) Соединения для лечения рака
CA2657107C (en) Human protein tyrosine phosphatase inhibitors and methods of use
JP4974463B2 (ja) インダン酢酸誘導体ならびに製薬学的薬剤としてのそれらの使用、中間体及び製造方法
US6448396B2 (en) Compounds useful as neuro-protective agents
JP4530668B2 (ja) インダン酢酸誘導体および薬剤としてのそれらの使用
US5952360A (en) Method for treating neuropathic pain
AU691191B2 (en) Novel (1-phenyl-1-heterocyclyl)alkane derivatives and their use as neuroprotective agents
US6472387B1 (en) Methods of using compounds as neuro-protective agents
JPWO2012033195A1 (ja) 複素環化合物
WO1999009829A1 (en) Method for treating pain
MXPA99004211A (en) Novel compounds useful as neuro-protective agents
JP2020513025A (ja) 置換されたｎ−アリールエチル−２−アリールキノリン−４−カルボキサミド類及びそれの使用
CZ20001206A3 (cs) Nové sloučeniny použitelné jako neuroprotektivní činidla

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees